<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563914</url>
  </required_header>
  <id_info>
    <org_study_id>ACT10420</org_study_id>
    <secondary_id>SSR97193</secondary_id>
    <nct_id>NCT00563914</nct_id>
  </id_info>
  <brief_title>A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria</brief_title>
  <official_title>An Open Label, 4 Escalating Dose, Randomized Multicentre Study Evaluating the Safety and Activity of Ferroquine Associated With Artesunate Versus a Positive Calibrator (Amodiaquine Associated With Artesunate) in African Adult Patients With Uncomplicated Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety of different doses of ferroquine with
      artesunate (AS) in adult African patients with uncomplicated malaria.

      The secondary objectives are to assess activity in reducing parasitemia and the
      pharmacokinetics of ferroquine and its metabolites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration is 30 days including a 2 day screening period, a 3 day treatment period
      with a follow-up period of 25 days. Patients remain hospitalized 4 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic safety :ALT, AST, Alkaline Phosphatase, Total Bilirubin</measure>
    <time_frame>Sreening , baseline, days D3,D5,D6,D7,D9,D14,D21 and D28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasite clearance assessed by repeated measurements of parasitemia</measure>
    <time_frame>Sreening, days D1(T6 and T12),D2 (T0 and T6), D3( T0, T6 and T12) ,D4,D7,D14,D21and D28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ferroquine assessed by repeated measurement of blood concentration</measure>
    <time_frame>up to 28 days after last dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferroquine (SSR97193)</intervention_name>
    <description>associated with artesunate</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amodiaquine</intervention_name>
    <description>associated with artesunate</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight between 50 kg and 90 kg with Body Mass Index &gt;18 kg/m²

          -  Presence of body temperature ≥ 37.5°C or history of fever within the last 24 hours

          -  Monoinfection with Plasmodium falciparum and parasitemia within the 100 to
             200,000/microL

        Exclusion Criteria:

          -  Hypersensitivity to quinoleines or artesunate

          -  History or presence of any clinically significant disease or symptoms which, in the
             judgment of the investigator, might confuse the interpretation of the safety and
             efficacy information

          -  Splenectomized patients

          -  Laboratory parameters outside normal ranges

          -  Presence of HBs antigen, anti-HCV antibodies and anti-HIV 1&amp;2 antibodies

          -  Cardio vascular and Electrocardiogram parameters outside normal values

          -  Presence of criteria of complicated malaria

          -  Permanent vomiting

          -  Previous treatment within 5 times the elimination half-life of any anti-malaria agents
             or with any marketed or investigational drugs (including St John's Wort) within 14
             days before administration, or within 5 times the elimination half-life of that drug,
             whichever the longest, especially CYP3A and 2D6 main substrates

          -  Positive results on urine drug screen for anti-malaria agents (aminoquinolines)

          -  History of drug or alcohol abuse (alcohol consumption &gt; 40 grams/day ; i. e. 2.5 beers
             of 33cl with 5 degrees of alcohol)

          -  Intention to use herbal medicine during the study period

          -  Immunization injection within last 15 days

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Supan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>URM (Unité de Recherches Médicales), Hôpital Albert Schweitzer, BP 118 Lambaréné, Gabon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
    <country>Kenya</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2007</study_first_submitted>
  <study_first_submitted_qc>November 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>December 18, 2009</last_update_submitted>
  <last_update_submitted_qc>December 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

